拉米夫定停药后肝炎69例临床分析

CLINICAL RESEARCH ON THE RECURRENCE OF HEPATITIS IN 69 PATIENTS WITH LAMINVUDINE STOPPED

目的探讨拉米夫定停药后肝炎的发生率、临床特点、机理及防治。方法对长期应用拉米夫定治疗后停药的患者进行1年以上的随访。结果拉米夫定停药后肝炎的总发生率为14·4%。结论对长期应用拉米夫定治疗的患者无论是否发生血清转换而停药,都要继续监测肝功能;对发生停药后肝炎患者,可再次使用拉米夫定或甘草酸类制剂治疗。

Objective To study the incidence, clinical features, mechanism, prevention and treatment of recurrence of hepatitis after stopping Laminvudine. Methods A one-year follow-up visit was made on the hepatitis patients who had a long-term application of Laminvudine and now had stopped it. Results The hepatitis recurrence rate for the patients who had stopped taking the Laminvudine was 14. 4%. Conclusion For the patients who have a long-term application of Laminvudine, whether the serum transformation happen or not, the liver function still should be continuously monitored. For the recurred patients of hepatitis who have stopped taking the Laminvudine, the Laminvudine or Dycyrrhizin Preparation should be used again.